Wall St. provides estimates for future stock prices of Eli Lilly from 2025 to 2030 based on projected revenue and net income.

Why Eli Lilly Stock Keeps Pushing Higher Eli Lilly (LLY) has been grinding higher again, with shares up roughly 2% over the ...

Eli Lilly's innovation and pipeline diversification support long-term growth, despite patent risks and competition. Read more ...

Lilly (LLY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Fundamentally, one of the central purposes of Direxion ETFs is to facilitate a convenient mechanism for speculation. Generally, those interested in leveraged or inverse positions must engage the ...

Eli Lilly leads incretins via Zepbound/Mounjaro, retatrutide at 28.7% loss, $50B R&D and US buildout, 2025 guidance, ...

Abivax stock skyrocketed in July after the company announced overwhelmingly positive topline results from its Phase 3 ...

The pharmaceutical stock can still deliver.

As Eli Lilly and Novo Nordisk scramble to bring an oral glucagon-like peptide 1 (GLP-1) receptor agonist to market for obesity, much smaller potential rival Structure Therapeutics spotlighted positive ...

GSK GSK stock has risen 18.6% in the past three months. The price recovery was backed by strong third-quarter results, ...

Eli Lilly and Company (NYSE:LLY) is included among the 14 Best US Stocks to Buy for Long Term. On December 3, Guggenheim ...

Jim Cramer, the charismatic host of CNBC’s Mad Money, has become a household name for investors seeking bold, actionable ...